Study of Efficacy and Safety of CTL019 in Adult ALL Patients

NCT02167360 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Did not enroll

Conditions

B-cell Acute Lymphoblastic Leukemia
Relapsed B-cell Acute Lymphoblastic Leukemia
Refractory B-cell Acute Lymphoblastic Leukemia

Interventions

DRUG: CTL019

Sponsor

Abramson Cancer Center at Penn Medicine